Analytical Data
-
Gene name
Y471H
- Application
-
Alternative Names
INN: Alteplase INN: Reteplase
-
Species
Human
-
Source
Baculovirus
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P00750
-
Expression Region
36-562aa(Y471H)
-
Molecular Weight
62.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Y471H is a recombinant protein variant derived from a critical protein involved in various biological processes, including signaling pathways and cellular interactions. The Y471H mutation, which replaces tyrosine with histidine at position 471, has garnered interest due to its potential impact on protein function and stability. Research indicates that such mutations can affect the protein's conformation, interaction with ligands, and overall biological activity. Understanding the implications of the Y471H variant is crucial in several fields, including drug development, where alterations in protein behavior can influence therapeutic efficacy. Moreover, studies on Y471H can provide insights into disease mechanisms, particularly in conditions where protein misfolding or dysregulation is implicated. Recent advances in recombinant DNA technology have facilitated the production of this variant, enabling comprehensive structural and functional analyses. These studies aim to elucidate the precise role of the Y471H mutation in cellular contexts and its potential as a biomarker or therapeutic target. By advancing our comprehension of this specific recombinant protein, researchers hope to devise novel strategies for intervention in diseases linked to similar protein alterations.
